Author: Ravi Shankar

Almere, the Netherlands
September 22, 2026

ASM, a materials discovery company and global leader in semiconductor wafer processing equipment, building on its leadership in atomic layer deposition and epitaxy, launches its XP8® Vertos™ Flowable Carbon, the market’s first plasma-enhanced chemical vapor deposition (PECVD) flowable carbon film. This innovation combines gap fill and planarization in a single PECVD process, reducing process complexity, improving topography control, and enabling 3D scaling. With initial deployment in high-volume manufacturing and applicability across both logic and memory devices, this next-generation patterning technology positions ASM to address a broader set of future patterning challenges as semiconductor scaling continues.
For more than two decades, chipmakers have relied on conventional carbon films not designed for the demands of modern 3D device architectures, which are reaching their limits in gap fill performance, topography control, and patterning fidelity. Vertos™ Flowable Carbon consolidates those critical patterning steps into a single platform, simplifying integration and reducing the number of process cycles required to achieve topography control.
As logic and memory scaling advances into complex 3D architectures, integration schemes that depend on multi-step fill, planarization, and patterning sequences increase risks to both yield and throughput.
“The industry’s ability to continue scaling increasingly complex devices depends as much on materials innovation as it does on architecture and design. Vertos™ Flowable Carbon demonstrates how ASM continues to translate materials discovery into manufacturing solutions that solve tomorrow’s integration challenges,” said Hichem M’Saad, Chief Executive Officer. “Every chip that ships with this technology represents faster, more efficient AI performance for the people and industries that depend on it.”
The semiconductor market is projected to reach $1.5 trillion in 2026 according to the Semiconductor Industry Association. Driven by the AI hypercycle and accelerating compute demand, chipmakers are scaling devices into increasingly complex 3D architectures, creating the need for new materials and process approaches to sustain performance gains. Materials innovation is now as critical as architectural design in enabling that progress. Vertos™ Flowable Carbon addresses that need, providing a purpose-built patterning solution for the complexity of next-generation devices.
“Conventional carbon films deposit material that conforms to the feature shape, which means topography problems propagate upward and require additional process steps to correct. Vertos™ Flowable Carbon changes that entirely. The material flows into the feature, fills from the bottom up, and self-planarizes, delivering a flat, uniform surface ready for the next patterning step,” said Tyler Sample, Vice President PECVD Key Product Unit Head. “The combination of engineered flowability, thermal stability, and area selective properties in a single PECVD platform is something the market has not seen before, and it opens a clear path forward for device architectures that existing carbon film technology cannot support.”

Flowable Carbon delivers a flat, uniform surface ready for the next patterning step.

Vertos™ Flowable Carbon is a novel PECVD process that fills even the most complex high-aspect-ratio features without voids or seams and self-planarizes across the wafer. The process operates within an all-in-one PECVD system, eliminating the need for downstream chemical mechanical planarization or etch-back steps, reducing both cost and defect risk in manufacturing. Unique film properties include improved planarization across substrates with diverse pattern density, increased thermal stability, and area selective deposition characteristics. This combination makes Vertos™ Flowable Carbon a scalable approach to patterning across current and future technology nodes.
For more information on ASM XP8® Vertos™ Flowable Carbon, visit ASM Flowable Carbon.

About ASM

ASM International N.V., headquartered in Almere, the Netherlands, and its subsidiaries design and manufacture equipment and process solutions to produce semiconductor devices for wafer processing, and have facilities in the United States, Europe, and Asia. ASM’s common stock trades on the Euronext Amsterdam Stock Exchange (symbol: ASM). For more information, visit ASM’s website at www.asm.com.

Contacts
Investor and media relations	Media
Victor Bareño	Alyx Cima
T: +31 88 100 8500	E: corporate.communications@asm.com
E: investor.relations@asm.com

Expanded program includes 4,000 m at Aljo and continued advancement of key regional targets, including Nahanni, Carr and Hawker

SASKATOON, Saskatchewan, Sept. 22, 2026 (GLOBE NEWSWIRE) — GFG Resources Inc. (TSXV: GFG | OTCQB: GFGSF) (“GFG” or the “Company”) provides an update on its 2026 exploration activities and announces an expanded exploration program at its 100%-owned Goldarm Property (“Goldarm” or the “Property”) in the Timmins Gold District of Ontario. (See Figures 1-6)

Results from the Company’s 82-hole sonic overburden drilling program, integrated with diamond drilling, till geochemistry, biogeochemistry and geological interpretation, continue to strengthen GFG’s regional targeting model and have identified multiple priority areas for follow-up.

Most notably, work at Hawker has outlined a large, multi-kilometre gold-in-till and bedrock anomaly while continued work at Nahanni has expanded the exploration opportunity beyond the areas tested by first-pass diamond drilling earlier this year.

Together with a growing pipeline of earlier-stage targets, these results reinforce GFG’s view that significant portions of Goldarm remain underexplored and provide multiple opportunities for new gold discoveries beneath extensive glacial cover. Importantly, this regional discovery upside is complemented by Aljo, where strong drill continuity and an increasingly well-defined mineralized system provide an opportunity to systematically expand a proven gold system and advance it toward a maiden resource.

Highlights:

• Hawker emerging as a compelling new discovery target. Sonic drilling has outlined a broad, approximately 2.5 kilometre (“km”) long gold-in-till anomaly across a favourable package of volcanic rocks and multiple regional structural corridors.
• Exceptional gold-grain response at Hawker remains open. Sonic hole GLM-R-073 returned 375 total gold grains over 16.3 metres (“m”) till interval, with strong anomalism extending through the till profile to bedrock. Importantly, GLM-R-073 is the northernmost hole drilled at Hawker and the northernmost hole of GFG’s entire 82-hole sonic program.
• Recent sonic anomalies validate Nahanni as a new gold discovery corridor. First-pass drilling intersected gold mineralization at all three target areas tested across an approximately 6 km corridor, including a peak result of 11.20 grams of gold per tonne (“g/t Au”) over 0.7 m within 1.97 g/t Au over 6.2 m. Subsequent sonic drilling has identified widespread gold-in-till anomalism along approximately 4 km of strike, including priority anomalies that remain untested by diamond drilling.
• Regional pipeline of gold targets continues to grow. Carr and several additional targets are being advanced through integrated sonic drilling, till geochemistry, biogeochemistry, prospecting and geological interpretation, while approximately 1,100 additional tree-bark samples are planned across broad portions of Goldarm.
• Strong continuity and growth potential at Aljo. Recent drilling has extended the Hangingwall (“HW”) Zone to approximately 300 m vertically, where it remains open, and has improved the Company’s understanding of the geometry and continuity of the mineralized system.
• 4,000 m of additional drilling at Aljo. The next phase will begin in Q4 with a focus on expansion at depth and testing the eastern and northwestern extensions of the broader Aljo system.
• Multiple value drivers. With Barrick funding and operating exploration at the Pen Gold Project, GFG is positioned to focus its treasury and technical resources on its 100%-owned Goldarm discovery platform while retaining significant exposure to exploration success at Pen.

Brian Skanderbeg, President and CEO of GFG, commented, “Our regional work is increasingly demonstrating the discovery potential and optionality we have across Goldarm. Hawker has quickly developed into one of the most compelling undrilled targets on the Property, with a large gold-in-till footprint, strong multi-element geochemistry, favourable structures and our strongest gold-grain response occurring at the northern edge of the current sonic drill coverage. Further overburden and bedrock drilling will be used to refine and vector in preparation for diamond drilling in Q1.

“At Nahanni, first-pass drilling already confirmed a new gold-bearing corridor over six kilometres, and our subsequent sonic work is identifying additional anomalies outside the areas tested to date. This is exactly what our regional exploration strategy is designed to do — use multiple datasets to identify large prospective systems, progressively refine the best targets and advance them toward drilling.

“With Aljo continuing to grow, Hawker advancing toward initial drilling, Nahanni moving into follow-up and a deep regional pipeline developing behind them, we believe Goldarm provides GFG with multiple opportunities to make meaningful new discoveries. Combined with Barrick funding exploration at Pen, GFG is very well positioned to aggressively pursue discovery and build value across our Timmins portfolio.”

Goldarm – Building a District-Scale Discovery Pipeline

Goldarm encompasses approximately 263 km², more than 30 km of prospective strike and extensive portions of the Pipestone and North Pipestone deformation corridors within the Timmins Gold District.

Large areas of Goldarm are concealed beneath glacial cover and have received limited systematic historical exploration.

GFG is using an integrated exploration approach combining:

• sonic base-of-till and top-of-bedrock drilling;
• conventional till sampling;
• biogeochemical sampling;
• prospecting and geological mapping;
• geophysical and structural interpretation; and
• diamond drilling.

This strategy is designed to progressively advance targets from large regional anomalies to focused, drill-ready opportunities.

The Company’s 82-hole sonic program has already identified multiple new gold and alteration trends and has played an important role in advancing Hawker, Nahanni, Carr and other emerging regional targets.

Hawker – Large-Scale Anomaly Advancing Toward Drilling

Hawker has emerged as one of GFG’s highest-priority regional discovery opportunities, approximately 6 km north of Nahanni, where a prospective package of mafic to felsic volcanic rocks is positioned adjacent to a large fault-bound sedimentary basin and several regional high-strain corridors. Widely spaced sonic drilling has defined a broad gold-in-till and bedrock anomaly extending across an approximately 2.5 km trend. With drill-hole spacing averaging approximately 1 km, the anomaly remains relatively unconstrained and provides significant opportunity for additional target refinement and vectoring toward priority areas for future diamond drilling.

Multiple holes have returned elevated gold-grain counts in till, together with anomalous gold in bedrock of up to 0.22 g/t Au over 3.0 m. The strongest response was returned from GLM-R-073, which yielded 375 total gold grains over a 16.3 m till interval, with consistently strong anomalism through the till profile to bedrock at 39.6 m. Significantly, GLM-R-073 is both the northernmost hole drilled at Hawker and the northernmost hole completed during GFG’s entire 82-hole sonic program. The strength and location of the anomaly leave the target open toward the interpreted up-ice source and into a largely untested northern stratigraphic panel.

Hawker is further supported by:

• a strong Au-Ag-Te-S geochemical association;
• multiple prospective regional structural corridors;
• high-strain zones with alteration, sulphidation, brecciation and veining;
• hessite (Ag-Te) identified in heavy mineral concentrates along with gold; and
• geochemical responses that compare favourably with benchmark signatures associated with known gold systems at Aljo and Montclerg.

The next phase of work will include infill biogeochemical sampling and targeted reverse circulation (“RC”) till drilling designed to better define the anomaly, constrain its potential bedrock source and prioritize targets for initial diamond drilling in Q1 2027.

The combination of scale, geochemistry, favourable geology, supporting mineralogy and significant remaining open space makes Hawker a compelling opportunity for a new regional discovery at Goldarm.

Nahanni – Expanding a New Gold Discovery Corridor

Nahanni represents the most advanced discovery generated from GFG’s regional exploration strategy.

Earlier in 2026, GFG completed 10 diamond drill holes totaling approximately 3,000 m across Nahanni West, Central and East along an approximately 6 km portion of the Pipestone Deformation Zone (“PDZ”).

Gold mineralization was intersected at all three target areas, including:

• 11.20 g/t Au over 0.7 m within 1.97 g/t Au over 6.2 m at Nahanni East;
• 5.12 g/t Au over 1.5 m within 0.20 g/t Au over 85.8 m at Nahanni Central; and
• 4.75 g/t Au over 1.0 m within 0.66 g/t Au over 9.0 m at Nahanni West.

The drilling identified strong deformation, quartz-carbonate veining, sulphidation, intense sericite-fuchsite alteration and felsic and porphyry dyking across the corridor. Broad mineralized intervals and alteration corridors support the interpretation of a large hydrothermal gold system with multiple structural controls.

Importantly, subsequent sonic drilling has further expanded the opportunity. Sonic drilling along approximately 4 km of the Nahanni trend has identified widespread gold-in-till anomalism, with multiple holes returning more than 30 gold grains per 10-kilogram (“kg”) sample.

The strongest gold-in-till anomaly identified to date occurs approximately 1 km southeast of Nahanni Central, where anomalism persists throughout an approximately 20 m-thick till profile.

Several of the strongest gold-in-till and bedrock anomalies identified by the regional program remain untested by diamond drilling, providing additional targets for the next phase of exploration.

GFG is prioritizing follow-up work at Nahanni Central and East, together with first pass testing of newly generated targets along the broader corridor in Q1 2027.

Regional Pipeline – Multiple Discovery Opportunities Across Goldarm

Beyond Hawker and Nahanni, GFG continues to advance a growing portfolio of regional targets.

At Carr, two sonic holes drilled approximately 500 m apart returned moderately to strongly anomalous gold-in-till values of greater than 50 gold grains per 10 kg sample together with anomalous gold in bedrock along a northeast-trending high-strain corridor adjacent to the Carr Porphyry.

Carr, Skutter, Anton and other emerging targets will continue to be evaluated through the integration of sonic drilling, till geochemistry, biogeochemical sampling, prospecting, geophysics and geological interpretation.

Through the remainder of 2026 and into 2027, GFG plans to complete:

• approximately 1,100 additional tree-bark samples across Goldarm;
• first-pass and infill biogeochemical programs;
• additional conventional till sampling and prospecting;
• targeted RC till drilling;
• follow-up diamond drilling at priority regional targets; and
• continued advancement of new targets toward drill-ready status.

At Montclerg, new diamond and overburden drilling programs are also being designed along strike of the known gold system to test for potential new zones and extensions.

The objective of this work is to maintain a deep and continuously evolving pipeline of discovery opportunities capable of supporting sustained exploration and drilling across Goldarm.

Aljo – Continued Expansion of a Growing Gold System

Aljo remains GFG’s principal advanced exploration target, where successive drill programs have established the HW Zone as a continuous and expanding component of the broader Aljo gold system. The zone has produced repeated significant intercepts, including 13.94 g/t Au over 7.1 m in ALJ-24-012, 6.62 g/t Au over 11.2 m, including 7.24 g/t Au over 10.2 m, in ALJ-24-020, and 4.13 g/t Au over 5.2 m, including 8.98 g/t Au over 2.2 m, in ALJ-24-018. Subsequent drilling demonstrated that this high-grade mineralization occurs within a broader mineralized envelope, highlighted by 1.05 g/t Au over 71.0 m, including 7.51 g/t Au over 3.0 m and 6.39 g/t Au over 2.0 m, in ALJ-25-030, together with 1.46 g/t Au over 14.3 m, including 9.36 g/t Au over 1.0 m, in ALJ-25-029.

The latest drilling continues to expand this established system. ALJ-26-039, drilled approximately 60 m down dip from ALJ-25-036, returned 0.43 g/t Au over 36.9 m, including 1.58 g/t Au over 1.5 m, and 0.70 g/t Au over 11.5 m, including 3.33 g/t Au over 1.5 m, extending the HW Zone to approximately 300 m vertical depth, where it remains open. At the shallow HW East extension, ALJ-26-041 returned 0.90 g/t Au over 7.7 m, including 3.17 g/t Au over 1.7 m, at approximately 50 m vertical depth. Visible gold was observed in both holes.

Together with the historical drilling, the results reinforce the continuity, scale and growth potential of the HW Zone, with approximately 4,000 m of additional drilling planned to expand the zone at depth and test the eastern and northwestern extensions of the broader Aljo system.

Multiple Drivers of Value Across GFG’s Timmins Portfolio

GFG’s expanded Goldarm program complements the Company’s strategic earn-in agreement with Barrick at the approximately 475 km² Pen Gold Project.

Under the agreement, Barrick may fund up to C$17.68 million in exploration and project expenditures to earn an initial 60% interest in Pen, while GFG retains significant exposure to future exploration success.

The transaction allows GFG to focus its treasury and technical resources on its 100%-owned Goldarm discovery platform, while Pen is advanced through a significant partner-funded exploration program.

With Aljo continuing to grow, Nahanni expanding as a new discovery corridor, Hawker advancing toward drill testing and a broad regional pipeline developing behind them, GFG believes it has multiple independent opportunities to drive discovery and create shareholder value across its Timmins portfolio.

About GFG Resources Inc.
GFG is a North American precious metals exploration company focused on district-scale gold opportunities in the Timmins Gold District of Ontario, Canada. The Company controls three highly prospective gold projects within one of the world’s most established gold camps.

GFG’s exploration strategy is focused on advancing the Aljo gold system, systematically generating and testing new discovery opportunities across the Goldarm Property and maintaining significant exposure to the advancement of the Pen Gold Project through its strategic earn-in agreement with Barrick.

Table 1: Summary of 2026 Aljo Drill Results
Hole ID	From (m)	To (m)	Length (m)	Au (g/t)	Target	VG
ALJ-26-039	283.0	293.5	10.5	0.20	Aljo HW
and	302.0	338.9	36.9	0.43	Aljo HW
incl.	325.5	327.0	1.5	1.58	Aljo HW
and	350.5	362.0	11.5	0.70	Aljo HW	+
incl.	350.5	352.0	1.5	3.33	Aljo HW	+
and	480.0	486.0	6.0	0.20	Aljo HW
ALJ-26-040	93.0	96.0	3.0	0.52	Aljo HW Ext
and	113.0	129.0	16.0	0.46	Aljo HW Ext
incl.	113.0	115.0	2.0	1.14	Aljo HW Ext
also incl.	117.0	117.7	0.7	1.39	Aljo HW Ext
ALJ-26-041	82.0	83.5	1.5	2.70	Aljo HW Ext	+
and	94.8	98.5	3.7	0.36	Aljo HW Ext
incl.	95.8	96.5	0.7	1.01	Aljo HW Ext
and	110.4	118.0	7.7	0.90	Aljo HW Ext	+
incl.	110.4	112.0	1.7	3.17	Aljo HW Ext	+
ALJ-26-042	92.5	94.5	2.0	1.49	Aljo HW Ext
and	98.5	99.5	1.0	1.10	Aljo HW Ext
and	126.0	130.0	4.0	0.27	Aljo HW Ext
ALJ-26-043	105.0	109.0	4.0	0.34	Aljo HW Ext
ALJ-26-044	NSI				Aljo HW Ext
Previously Released 2025 Phase 2 Assays
ALJ-25-029	7.7	22.0	14.3	1.46	HW	+
incl.	19.5	20.5	1.0	9.36	HW	+
and	30.5	45.0	14.5	0.58	HW	+
and	50.5	58.8	8.3	0.52	HW
and	127.8	128.8	1.0	2.74	Main
and	131.5	132.2	0.7	6.65	Main
and	190.0	199.0	9.0	1.15	Main
incl.	197.0	198.0	1.0	3.55	Main
and	335.0	341.5	6.5	1.15	FW3
incl.	339.3	340.0	0.7	4.13	FW3
and	389.0	390.5	1.5	4.22	FW4
ALJ-25-030	11.5	82.5	71.0	1.05	HW	+
incl.	15.5	18.5	3.0	7.51	HW	+
also incl.	26.0	27.0	1.0	3.26	HW
also incl.	31.5	32.8	1.3	4.97	HW
also incl.	46.5	47.5	1.0	4.09	HW
also incl.	70.5	72.5	2.0	6.39	HW	+
also incl.	77.5	78.5	1.0	5.00	HW
and	97.5	99.0	1.5	2.83	HW
and	113.4	114.5	1.1	1.01	HW
and	176.0	177.0	1.0	1.00	Main
and	209.5	212.0	2.5	1.28	Main
and	224.0	225.0	1.0	1.88	Main
ALJ-25-018ext	568.0	570.0	2.0	2.57	FW
incl.	569.0	570.0	1.0	4.63	FW
ALJ-25-031	124.8	126.3	1.5	1.18	HW
and	133.1	134.6	1.5	4.67	HW
and	251.9	252.7	0.8	1.97	Main
and	268.9	270.4	1.5	2.51	Main
and	297.6	298.1	0.5	1.27	Main
and	325.6	326.4	0.8	11.40	Main
ALJ-25-032	29.5	34.0	4.5	3.68	HW	+
incl.	29.5	30.0	0.5	17.40	HW	+
and	89.3	92.0	2.7	2.80	HW
and	130.0	131.0	1.0	2.86	Main
and	146.9	147.7	0.8	4.92	Main	+
and	167.0	168.0	1.0	1.40	Main
ALJ-25-033	25.2	31.0	5.8	2.03	HW	+
incl.	27.2	27.7	0.5	10.40	HW	+
ALJ-25-034	62.4	63.6	1.2	1.27	HW
and	74.0	75.0	1.0	1.08	HW
ALJ-25-035	147.3	150.4	3.1	0.98	HW
and	159.9	162.0	2.1	10.45	HW	+
incl.	159.9	160.9	0.9	22.90	HW	+
and	171.2	186.5	15.3	1.51	HW	+
incl.	175.0	175.9	0.9	6.98	HW	+
ALJ-25-036(2)	291.3	342.8	51.5	1.01	HW
incl.	321.0	326.0	5.0	6.36	HW
ALJ-25-037	132.0	148.0	16.0	1.23	East HW	+
incl.	142.0	144.0	2.0	7.23	East HW	+
and	156.2	158.2	2.0	1.07	East HW	+
and	170.9	172.7	1.8	2.40	East HW	+
incl.	171.9	172.7	0.8	5.00	East HW
ALJ-25-038	5.2	8.2	3.0	1.15	East Main
and	65.2	72.3	7.1	1.28	East Main
and	93.8	96.2	2.4	3.21	East Main
and	123.0	128.3	5.3	2.23	East Main
incl.	124.9	125.4	0.5	13.30	East Main

Footnotes:
⁽¹⁾ Drill intercepts are presented using a 0.20 g/t Au cut-off and as drilled length with a minimum 1 gram-metre product. Composites include internal dilution of up to 3 m at grades less than 0.20 g/t Au. Included intervals are calculated using a 3 g/t cut-off at a minimum 1 gram-metre product unless otherwise stated. True width is estimated to be 30 to 90% drilled length.
⁽²⁾ Includes a single 5 metre interval below 0.2 g/t Au cut-off.

Sampling and Quality Control
All scientific and technical information contained in this news release has been prepared under the supervision of Anders Carlson, P.Geo., Vice President, Exploration of GFG, a qualified person within the meaning of National Instrument 43-101.

Drill core samples are analyzed for gold by Activation Laboratories Ltd. in Timmins, Ontario. The Company maintains a quality assurance and quality control program that includes the insertion and monitoring of certified reference materials, blanks and duplicates. Samples returning elevated gold values are subject to additional analytical procedures where appropriate.

Figure 1: Regional Map of GFG Gold Projects in the Timmins Gold District

Figure 2: Goldarm Property Plan View Map

Figure 3: Nahanni Gold Target in Plan View

Figure 4: Goldarm Regional Gold Targets

Figure 5: Aljo Gold System Plans Map

Figure 6: Aljo Gold System Cross Section Map

For further information, please contact:
Brian Skanderbeg, President & CEO
or
Marc Lepage, Vice President, Business Development
Phone: (306) 931-0930
Email: info@gfgresources.com
Website: www.gfgresources.com  

Stay Connected with Us
X (Twitter): GFGResources
LinkedIn: https://www.linkedin.com/company/gfgresources/
Facebook: https://www.facebook.com/GFGResourcesInc/

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTION REGARDING FORWARD-LOOKING INFORMATION

All statements, other than statements of historical fact, contained in this news release constitute “forward-looking information” within the meaning of applicable Canadian securities laws and “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 (referred to herein as “forward-looking statements”). Forward-looking statements include, but are not limited to, the Company’s future exploration plans with respect to its property interests and the timing thereof, the prospective nature of the projects, future price of gold, success of exploration activities and metallurgical test work, permitting time lines, currency exchange rate fluctuations, requirements for additional capital, government regulation of exploration work, environmental risks, unanticipated reclamation expenses, title disputes or claims and limitations on insurance coverage. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate” or “believes”, or the negative connotation thereof or variations of such words and phrases or state that certain actions, events or results, “may”, “could”, “would”, “will”, “might” or “will be taken”, “occur” or “be achieved” or the negative connotation thereof.

All forward-looking statements are based on various assumptions, including, without limitation, the expectations and beliefs of management, the assumed long-term price of gold, that the Company will receive required permits and access to surface rights, that the Company can access financing, appropriate equipment and sufficient labour, and that the political environment within Canada will continue to support the development of mining projects. In addition, the similarity or proximity of other gold deposits to the Company’s projects is not necessarily indicative of the geological setting, alteration and mineralization of the Goldarm Property, the Pen Gold Project and the Dore Gold Project.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of GFG to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: actual results of current exploration activities; environmental risks; future prices of gold; operating risks; accidents, labour issues and other risks of the mining industry; availability of capital, delays in obtaining government approvals or financing; and other risks and uncertainties. These risks and uncertainties and the additional risks described in the Company’s most recently filed annual and interim MD&A are not and should not be construed as being exhaustive.

Although GFG has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. In addition, forward-looking statements are provided solely for the purpose of providing information about management’s current expectations and plans and allowing investors and others to get a better understanding of our operating environment. Accordingly, readers should not place undue reliance on forward-looking statements.

Forward-looking statements in this news release are made as of the date hereof and GFG assumes no obligation to update any forward-looking statements, except as required by applicable laws.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/b96918c6-1f46-4496-a9e5-8ed6f2f27d25

https://www.globenewswire.com/NewsRoom/AttachmentNg/7d2bfddb-b646-4188-8fa8-fcb60fa957ec

https://www.globenewswire.com/NewsRoom/AttachmentNg/25631bf9-5b94-45db-9610-6de027dd9bf0

https://www.globenewswire.com/NewsRoom/AttachmentNg/6e260008-5603-4099-8bb1-2db5306f580d

https://www.globenewswire.com/NewsRoom/AttachmentNg/8011f5b1-f821-48e7-89d9-902783e3bcd2

https://www.globenewswire.com/NewsRoom/AttachmentNg/4b99cc9a-14ad-4624-8d7c-3863e975056b

FIXING OF COUPON FROM 23 september 2026

Interest coupon for the period 23.09.2026 – 23.12.2026:

DK0030576236, (Tier 2), maturity 2056, 3 months CIBOR; 2.58% + 1.40% = 3.98% p.a.

Contact

Please direct any questions regarding this announcement to:

Investors and equity analysts:

Head of Investor Relations and ESG

Mads Thinggaard

Mobile no. +45 2025 5469

Attachment

• Alm. Brand – Fixing of Coupon Tier 2 – 23 September 2026

FIXING OF COUPON FROM 23 september 2026

Interest coupon for the period 23.09.2026 – 23.12.2026:

DK0030576236, (Tier 2), maturity 2056, 3 months CIBOR; 2.58% + 1.40% = 3.98% p.a.

Contact

Please direct any questions regarding this announcement to:

Investors and equity analysts:

Head of Investor Relations and ESG

Mads Thinggaard

Mobile no. +45 2025 5469

Attachment

• Alm. Brand – Fixing of Coupon Tier 2 – 23 September 2026

MONTRÉAL, Sept. 22, 2026 (GLOBE NEWSWIRE) — Air Canada today announced that its leadership development program, Elevate, has been recognized with a Brandon Hall Group Gold HCM Excellence Award in the category of Best Leadership Development Program.

Created in response to employee feedback, Elevate was designed to help establish a shared foundation for leadership across Air Canada. The program equips leaders with practical tools and experiences that support learning, application, and reflection, while reinforcing the company’s leadership commitments: inspiring people, enabling performance, and finding solutions.

“This recognition reflects Air Canada’s commitment to developing strong, consistent leadership across our organization,” said Arielle Meloul-Wechsler, Executive Vice President, Chief Human Resources Officer and Public Affairs at Air Canada. “Elevate demonstrates our belief that great leadership is essential to fostering an engaged workforce, delivering strong performance, and creating an environment where people can do their best work. We are proud of everyone who contributed to making this program a success.”

The Brandon Hall Group Excellence Awards recognize organizations that have successfully developed and implemented programs, strategies, and tools that drive measurable business results through human capital management initiatives.

Since its launch, Elevate has helped strengthen leadership across Air Canada by giving leaders a common framework to apply new skills, and support employees in doing their best work.

For more information about careers and leadership development opportunities at Air Canada, visit aircanada.com/careers.

About Air Canada

Air Canada is Canada’s largest airline, the country’s flag carrier and a founding member of Star Alliance, the world’s most comprehensive air transportation network. Headquartered in Montréal, Air Canada provides scheduled service directly to more than 180 airports in Canada, the United States and internationally on six continents. It holds a Four-Star ranking from Skytrax. Air Canada’s Aeroplan program is Canada’s premier travel loyalty program, with more than 10 million members worldwide. Members can earn or redeem points on the world’s largest airline partner network of more than 50 airlines, plus through an extensive range of merchandise, hotel and car rental partners. Through Air Canada Vacations, it offers a selection of vacation and Flight & Hotel packages, tours, cruises, car rentals, and experiences. Its freight division, Air Canada Cargo, provides air freight lift and connectivity to hundreds of destinations across six continents using Air Canada’s passenger and freighter aircraft. Air Canada’s climate-related ambition includes a long-term aspirational goal of net-zero greenhouse gas emissions by 2050. For additional information, please see Air Canada’s TCFD disclosure. Air Canada shares are publicly traded on the TSX (AC).

Contacts:  media@aircanada.ca

Internet:    aircanada.com/media

Read our annual report Here

Sign up for Air Canada news: aircanada.com

Media Resources:
Photos
Videos
B-Roll
Articles

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0bd06cdf-1cfb-4c3e-ad64-781a24abf5d7

MONTRÉAL, Sept. 22, 2026 (GLOBE NEWSWIRE) — Air Canada today announced that its leadership development program, Elevate, has been recognized with a Brandon Hall Group Gold HCM Excellence Award in the category of Best Leadership Development Program.

Created in response to employee feedback, Elevate was designed to help establish a shared foundation for leadership across Air Canada. The program equips leaders with practical tools and experiences that support learning, application, and reflection, while reinforcing the company’s leadership commitments: inspiring people, enabling performance, and finding solutions.

“This recognition reflects Air Canada’s commitment to developing strong, consistent leadership across our organization,” said Arielle Meloul-Wechsler, Executive Vice President, Chief Human Resources Officer and Public Affairs at Air Canada. “Elevate demonstrates our belief that great leadership is essential to fostering an engaged workforce, delivering strong performance, and creating an environment where people can do their best work. We are proud of everyone who contributed to making this program a success.”

The Brandon Hall Group Excellence Awards recognize organizations that have successfully developed and implemented programs, strategies, and tools that drive measurable business results through human capital management initiatives.

Since its launch, Elevate has helped strengthen leadership across Air Canada by giving leaders a common framework to apply new skills, and support employees in doing their best work.

For more information about careers and leadership development opportunities at Air Canada, visit aircanada.com/careers.

About Air Canada

Air Canada is Canada’s largest airline, the country’s flag carrier and a founding member of Star Alliance, the world’s most comprehensive air transportation network. Headquartered in Montréal, Air Canada provides scheduled service directly to more than 180 airports in Canada, the United States and internationally on six continents. It holds a Four-Star ranking from Skytrax. Air Canada’s Aeroplan program is Canada’s premier travel loyalty program, with more than 10 million members worldwide. Members can earn or redeem points on the world’s largest airline partner network of more than 50 airlines, plus through an extensive range of merchandise, hotel and car rental partners. Through Air Canada Vacations, it offers a selection of vacation and Flight & Hotel packages, tours, cruises, car rentals, and experiences. Its freight division, Air Canada Cargo, provides air freight lift and connectivity to hundreds of destinations across six continents using Air Canada’s passenger and freighter aircraft. Air Canada’s climate-related ambition includes a long-term aspirational goal of net-zero greenhouse gas emissions by 2050. For additional information, please see Air Canada’s TCFD disclosure. Air Canada shares are publicly traded on the TSX (AC).

Contacts:  media@aircanada.ca

Internet:    aircanada.com/media

Read our annual report Here

Sign up for Air Canada news: aircanada.com

Media Resources:
Photos
Videos
B-Roll
Articles

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0bd06cdf-1cfb-4c3e-ad64-781a24abf5d7

Fairfax, Virginia, Sept. 22, 2026 (GLOBE NEWSWIRE) — Visium Technologies, Inc. (OTCID: VISM) (the “Company”) today announced that it has executed a non-binding term sheet with counterparties concerning a proposed assignment of specified contract-use, offtake, and deployment rights.

Under the term sheet, those rights would be assigned into a newly formed Indonesian limited-liability PMA company. A wholly owned Delaware subsidiary of the Company would hold a 99 percent interest in that PMA company. The proposed transaction is an assignment of identified rights. It is not an acquisition of the equity of any existing operating company. It would not cause the Company to manufacture semiconductor devices or to assume historical liabilities of the design firm.

Paul R. Taylor, Chairman and Chief Executive Officer, said: “Markets do not pay for adjectives. They pay for rights that survive a closing. We are not announcing a factory, a partner, or a watt. We are putting a defined bundle of rights into a clean vehicle, leaving every inherited liability where it belongs, and refusing to call the work finished until the last condition exists in fact.”

The term sheet is non-binding except for customary provisions on exclusivity, confidentiality, expenses, and governing law. Economic terms remain subject to Board authorization. Any closing consideration is expected to consist of a newly designated series of non-voting convertible preferred stock issued in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b). No cash is payable at a closing unless the Board separately authorizes a cash component.

Closing, if it occurs, remains subject to conditions that have not been satisfied, including written device specifications, required third-party and change-of-control consents, U.S. export-control classification and screening, Indonesian corporate and special-economic-zone approvals, site rights that survive closing, and corporate approvals required under Florida law. There can be no assurance that those conditions will be satisfied, that a definitive agreement will be executed, or that the transaction will close on the contemplated terms or at all.

Certain persons who beneficially own voting securities of the Company, and the Company’s Chairman and Chief Executive Officer, have relationships with parties expected to participate in the negotiation or performance of the proposed transaction. Those relationships will be disclosed in the Company’s filings to the extent required by the Exchange Act and Florida law. The term sheet requires review under Section 607.0832 of the Florida Business Corporation Act. That review has not been completed.

The Company is not announcing a partnership, a manufacturing arrangement, allocated power capacity, or projected revenue. The Company will file a Current Report on Form 8-K if and when it enters a material definitive agreement or completes a transaction that requires disclosure under the Exchange Act. Investors should rely solely on the Company’s filings with the Securities and Exchange Commission.

About Visium Technologies, Inc.
Visium Technologies, Inc. is a publicly traded technology holding company headquartered in Fairfax, Virginia. The company focuses on advanced technology platforms, AI-driven operational systems, analytics, and enterprise intelligence solutions.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to platform capabilities, anticipated operational benefits, customer adoption, future deployments, and market opportunities. Actual results may differ materially from those expressed or implied due to a variety of risks and uncertainties, including technology performance, market conditions, customer adoption rates, regulatory considerations, and other factors. Visium Technologies, Inc. undertakes no obligation to update forward-looking statements except as required by applicable law.

Media Contacts
Visium Technologies — Press: press@visiumtechnologies.com
Visium Technologies — Investor Relations: ir@visiumtechnologies.com
IR Concierge: 888-344-9850
Visium Technologies

Fairfax, Virginia, Sept. 22, 2026 (GLOBE NEWSWIRE) — Visium Technologies, Inc. (OTCID: VISM) (the “Company”) today announced that it has executed a non-binding term sheet with counterparties concerning a proposed assignment of specified contract-use, offtake, and deployment rights.

Under the term sheet, those rights would be assigned into a newly formed Indonesian limited-liability PMA company. A wholly owned Delaware subsidiary of the Company would hold a 99 percent interest in that PMA company. The proposed transaction is an assignment of identified rights. It is not an acquisition of the equity of any existing operating company. It would not cause the Company to manufacture semiconductor devices or to assume historical liabilities of the design firm.

Paul R. Taylor, Chairman and Chief Executive Officer, said: “Markets do not pay for adjectives. They pay for rights that survive a closing. We are not announcing a factory, a partner, or a watt. We are putting a defined bundle of rights into a clean vehicle, leaving every inherited liability where it belongs, and refusing to call the work finished until the last condition exists in fact.”

The term sheet is non-binding except for customary provisions on exclusivity, confidentiality, expenses, and governing law. Economic terms remain subject to Board authorization. Any closing consideration is expected to consist of a newly designated series of non-voting convertible preferred stock issued in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b). No cash is payable at a closing unless the Board separately authorizes a cash component.

Closing, if it occurs, remains subject to conditions that have not been satisfied, including written device specifications, required third-party and change-of-control consents, U.S. export-control classification and screening, Indonesian corporate and special-economic-zone approvals, site rights that survive closing, and corporate approvals required under Florida law. There can be no assurance that those conditions will be satisfied, that a definitive agreement will be executed, or that the transaction will close on the contemplated terms or at all.

Certain persons who beneficially own voting securities of the Company, and the Company’s Chairman and Chief Executive Officer, have relationships with parties expected to participate in the negotiation or performance of the proposed transaction. Those relationships will be disclosed in the Company’s filings to the extent required by the Exchange Act and Florida law. The term sheet requires review under Section 607.0832 of the Florida Business Corporation Act. That review has not been completed.

The Company is not announcing a partnership, a manufacturing arrangement, allocated power capacity, or projected revenue. The Company will file a Current Report on Form 8-K if and when it enters a material definitive agreement or completes a transaction that requires disclosure under the Exchange Act. Investors should rely solely on the Company’s filings with the Securities and Exchange Commission.

About Visium Technologies, Inc.
Visium Technologies, Inc. is a publicly traded technology holding company headquartered in Fairfax, Virginia. The company focuses on advanced technology platforms, AI-driven operational systems, analytics, and enterprise intelligence solutions.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to platform capabilities, anticipated operational benefits, customer adoption, future deployments, and market opportunities. Actual results may differ materially from those expressed or implied due to a variety of risks and uncertainties, including technology performance, market conditions, customer adoption rates, regulatory considerations, and other factors. Visium Technologies, Inc. undertakes no obligation to update forward-looking statements except as required by applicable law.

Media Contacts
Visium Technologies — Press: press@visiumtechnologies.com
Visium Technologies — Investor Relations: ir@visiumtechnologies.com
IR Concierge: 888-344-9850
Visium Technologies

Initial tranche assists CannEpil® development and commercialization

Financing comes as FDA and Congress increase focus on advancing and incentivizing regulated development of botanical and plant-derived medicines

FORT LAUDERDALE, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) — Endovia Health Sciences, Inc. (NYSE American: EDVA) (“Endovia” or the “Company”), a cannabinoid health sciences company, today announced that it has closed initial funding from C/M Capital Master Fund, LP (“C/M Capital”), representing the first tranche investment commitment previously announced in connection with the Company’s exclusive global licensing agreement for CannEpil® with Argent BioPharma Limited.

The capital is to advance the development and commercialization of CannEpil®, including Endovia’s U.S. FDA-regulated veterinary development program and international commercialization initiatives.

Endovia’s acquisition of exclusive worldwide rights to CannEpil®. C/M Capital committed capital to support regulatory advancement, clinical development planning and commercialization of the product.

“When we acquired the global rights to CannEpil, we laid out a clear strategy: secure a differentiated pharmaceutical cannabinoid asset, capitalize the program, advance it through established regulatory pathways and build a broader cannabinoid health sciences platform around it,” said Brady Cobb, Interim Chief Executive Officer of Endovia Health Sciences. “With this initial funding now closed, we are putting capital directly behind that strategy at what we believe is an increasingly important time for cannabinoid science and federal regulatory policy.”

Advancing CannEpil® Through Established FDA Pathways

The financing follows a series of milestones for Endovia’s CannEpil® development program.

The U.S. Food and Drug Administration’s Center for Veterinary Medicine previously established Investigational New Animal Drug (“INAD”) File No. 14145 for the CannEpil® veterinary development program, formally initiating the FDA regulatory process for development of CannEpil® as an investigational veterinary pharmaceutical.

Endovia is initially pursuing CannEpil® for the management of cancer-related pain in companion animals, beginning with canine oncology, and is working with Lupvindol Biosciences Ltd., its veterinary development partner, to advance the program through the applicable FDA regulatory process.

The Company also continues to pursue international commercialization opportunities for CannEpil® and evaluate additional cannabinoid formulations and intellectual property for potential licensing, acquisition or strategic collaboration.

Federal Momentum Toward Botanical Drug Development

Endovia believes its investment in cannabinoid pharmaceutical development is occurring against an increasingly constructive federal backdrop for the scientific development of botanical and plant-derived medicines.

The FDA recently launched an initiative seeking public input on opportunities to advance botanical drug development in the United States, including regulatory challenges facing botanical drug developers, innovative approaches to accelerate development, potential updates to FDA guidance and resources, quality standards and clinical study design. The initiative builds upon the FDA’s existing botanical drug regulatory framework, under which plant-derived products may be developed through established FDA drug-approval pathways. FDA materials addressing drug development from the cannabis plant have also identified the Agency’s botanical drug guidance as applicable to the use of botanicals, including cannabis, as sources for drug development.

Congress is also considering new incentives intended to encourage investment in FDA-regulated botanical medicines. On August 27, 2026, Representatives Lauren Boebert and Derrick Van Orden introduced H.R. 10150, the Advancing Botanical Drug Development Act of 2026, which was referred to the House Committee on Energy and Commerce. The proposed legislation would amend Section 505 of the Federal Food, Drug, and Cosmetic Act to provide qualifying botanical drugs approved through the FDA’s Section 505(b)(1) pathway with a 12-year period of market exclusivity, during which certain subsequent applications relying upon the approved botanical drug could not become effective.

In its findings, H.R. 10150 recognizes both the scientific potential and unique development challenges associated with botanical medicines and states that existing intellectual-property and regulatory-exclusivity frameworks may provide insufficient incentives for private investment in botanical drug research and development. The legislation expressly seeks to encourage the development and approval of evidence-based, FDA-regulated botanical drugs while maintaining the safety and effectiveness standards applicable to other FDA-regulated drugs.

“We believe these developments are significant for the broader cannabinoid sciences industry,” Cobb said. “The FDA already has an established regulatory framework for botanical drug development, and cannabis has been recognized within the Agency’s botanical drug development materials. We are now seeing renewed attention from both FDA and Congress around how sophisticated plant-derived medicines can be developed, evaluated and ultimately brought to market through rigorous, science-based regulatory pathways.”

Cobb continued, “The proposed 12-year exclusivity period is particularly noteworthy because access to capital and protection of the substantial investment required for pharmaceutical development are critical to building viable programs around complex plant-derived medicines. While H.R. 10150 remains proposed legislation, we believe its introduction, together with FDA’s renewed focus on botanical drug development, reflects meaningful federal attention to creating an environment capable of supporting greater scientific and private-sector investment in this area.”

About Endovia Health Sciences

Endovia Health Sciences, Inc. (NYSE American: EDVA) is a cannabinoid health sciences company focused on building a diversified platform across pharmaceutical development, FDA-regulated human and veterinary therapeutics, international pharmaceutical commercialization and cannabinoid-based wellness products.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of applicable federal securities laws, including statements regarding the development and commercialization of CannEpil®; the intended use and anticipated benefits of financing proceeds; future funding; FDA and other regulatory activities; potential changes in federal laws, regulations and policies affecting botanical drugs, cannabis and cannabinoids; plans and expectations for commercialization efforts including for veterinary uses and U.S. and international commercialization; potential licensing and acquisition opportunities; and the Company’s strategy to develop and expand its cannabinoid health sciences platform.

Forward-looking statements are based on current expectations, estimates, projections and assumptions and involve risks and uncertainties that could cause actual results to differ materially. These risks include the Company’s ability to obtain additional financing; successfully develop, obtain regulatory authorization for and commercialize CannEpil® or other products; maintain its rights under applicable license agreements; the enactment, implementation or impact of proposed legislation or regulatory initiatives; the occurrence of greater scientific and private-sector investment in botanical drug pathways, our ability to identify and consummate licensing, acquisition or strategic transactions; comply with NYSE American continued listing standards; and successfully execute our business strategy, our ability to complete required studies, establish product safety and efficacy, obtain and maintain regulatory authorizations, the risk that competitors market the same or similar products, our ability execute commercialization or strategic-partnering arrangements, the risk that that the market or demand for any resulting product we seek to commercialize in the future could be less than expected or projected, our ability to meet our debt obligations and the negative financial and operational consequences of failing to do so, the possibility that our expectations and perceived benefits with respect to our business and product development plan and strategic transactions we may pursue prove to be incorrect, and risks with respect to our ability to negotiate and execute definitive agreements, satisfy closing conditions, obtain required approvals with respect to any such strategic transaction. There can be no assurance that the Company’s goals and milestones will be achieved, that the Company or its collaborators will receive or maintain necessary regulatory authorizations or that any initiative will ultimately generate revenue.

There can be no assurance that additional funding will be received, H.R. 10150 or other proposed legislation will be enacted in its current form or at all, regulatory policies will change, regulatory or commercialization milestones will be achieved, or any product or initiative will ultimately generate revenue. Additional risks are described in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, the Form S-1 filed on August 7, 2026, as amended, and the final prospectus filed pursuant to Rule 424(b)(3) on August 28, 2026.

Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any such statements whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Contact
Endovia Health Sciences
investors@endoviasciences.com

Media Contact
Angela Gorman
AMWPR
angela@amwpr.com
917-348-0083

Initial tranche assists CannEpil® development and commercialization

Financing comes as FDA and Congress increase focus on advancing and incentivizing regulated development of botanical and plant-derived medicines

FORT LAUDERDALE, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) — Endovia Health Sciences, Inc. (NYSE American: EDVA) (“Endovia” or the “Company”), a cannabinoid health sciences company, today announced that it has closed initial funding from C/M Capital Master Fund, LP (“C/M Capital”), representing the first tranche investment commitment previously announced in connection with the Company’s exclusive global licensing agreement for CannEpil® with Argent BioPharma Limited.

The capital is to advance the development and commercialization of CannEpil®, including Endovia’s U.S. FDA-regulated veterinary development program and international commercialization initiatives.

Endovia’s acquisition of exclusive worldwide rights to CannEpil®. C/M Capital committed capital to support regulatory advancement, clinical development planning and commercialization of the product.

“When we acquired the global rights to CannEpil, we laid out a clear strategy: secure a differentiated pharmaceutical cannabinoid asset, capitalize the program, advance it through established regulatory pathways and build a broader cannabinoid health sciences platform around it,” said Brady Cobb, Interim Chief Executive Officer of Endovia Health Sciences. “With this initial funding now closed, we are putting capital directly behind that strategy at what we believe is an increasingly important time for cannabinoid science and federal regulatory policy.”

Advancing CannEpil® Through Established FDA Pathways

The financing follows a series of milestones for Endovia’s CannEpil® development program.

The U.S. Food and Drug Administration’s Center for Veterinary Medicine previously established Investigational New Animal Drug (“INAD”) File No. 14145 for the CannEpil® veterinary development program, formally initiating the FDA regulatory process for development of CannEpil® as an investigational veterinary pharmaceutical.

Endovia is initially pursuing CannEpil® for the management of cancer-related pain in companion animals, beginning with canine oncology, and is working with Lupvindol Biosciences Ltd., its veterinary development partner, to advance the program through the applicable FDA regulatory process.

The Company also continues to pursue international commercialization opportunities for CannEpil® and evaluate additional cannabinoid formulations and intellectual property for potential licensing, acquisition or strategic collaboration.

Federal Momentum Toward Botanical Drug Development

Endovia believes its investment in cannabinoid pharmaceutical development is occurring against an increasingly constructive federal backdrop for the scientific development of botanical and plant-derived medicines.

The FDA recently launched an initiative seeking public input on opportunities to advance botanical drug development in the United States, including regulatory challenges facing botanical drug developers, innovative approaches to accelerate development, potential updates to FDA guidance and resources, quality standards and clinical study design. The initiative builds upon the FDA’s existing botanical drug regulatory framework, under which plant-derived products may be developed through established FDA drug-approval pathways. FDA materials addressing drug development from the cannabis plant have also identified the Agency’s botanical drug guidance as applicable to the use of botanicals, including cannabis, as sources for drug development.

Congress is also considering new incentives intended to encourage investment in FDA-regulated botanical medicines. On August 27, 2026, Representatives Lauren Boebert and Derrick Van Orden introduced H.R. 10150, the Advancing Botanical Drug Development Act of 2026, which was referred to the House Committee on Energy and Commerce. The proposed legislation would amend Section 505 of the Federal Food, Drug, and Cosmetic Act to provide qualifying botanical drugs approved through the FDA’s Section 505(b)(1) pathway with a 12-year period of market exclusivity, during which certain subsequent applications relying upon the approved botanical drug could not become effective.

In its findings, H.R. 10150 recognizes both the scientific potential and unique development challenges associated with botanical medicines and states that existing intellectual-property and regulatory-exclusivity frameworks may provide insufficient incentives for private investment in botanical drug research and development. The legislation expressly seeks to encourage the development and approval of evidence-based, FDA-regulated botanical drugs while maintaining the safety and effectiveness standards applicable to other FDA-regulated drugs.

“We believe these developments are significant for the broader cannabinoid sciences industry,” Cobb said. “The FDA already has an established regulatory framework for botanical drug development, and cannabis has been recognized within the Agency’s botanical drug development materials. We are now seeing renewed attention from both FDA and Congress around how sophisticated plant-derived medicines can be developed, evaluated and ultimately brought to market through rigorous, science-based regulatory pathways.”

Cobb continued, “The proposed 12-year exclusivity period is particularly noteworthy because access to capital and protection of the substantial investment required for pharmaceutical development are critical to building viable programs around complex plant-derived medicines. While H.R. 10150 remains proposed legislation, we believe its introduction, together with FDA’s renewed focus on botanical drug development, reflects meaningful federal attention to creating an environment capable of supporting greater scientific and private-sector investment in this area.”

About Endovia Health Sciences

Endovia Health Sciences, Inc. (NYSE American: EDVA) is a cannabinoid health sciences company focused on building a diversified platform across pharmaceutical development, FDA-regulated human and veterinary therapeutics, international pharmaceutical commercialization and cannabinoid-based wellness products.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of applicable federal securities laws, including statements regarding the development and commercialization of CannEpil®; the intended use and anticipated benefits of financing proceeds; future funding; FDA and other regulatory activities; potential changes in federal laws, regulations and policies affecting botanical drugs, cannabis and cannabinoids; plans and expectations for commercialization efforts including for veterinary uses and U.S. and international commercialization; potential licensing and acquisition opportunities; and the Company’s strategy to develop and expand its cannabinoid health sciences platform.

Forward-looking statements are based on current expectations, estimates, projections and assumptions and involve risks and uncertainties that could cause actual results to differ materially. These risks include the Company’s ability to obtain additional financing; successfully develop, obtain regulatory authorization for and commercialize CannEpil® or other products; maintain its rights under applicable license agreements; the enactment, implementation or impact of proposed legislation or regulatory initiatives; the occurrence of greater scientific and private-sector investment in botanical drug pathways, our ability to identify and consummate licensing, acquisition or strategic transactions; comply with NYSE American continued listing standards; and successfully execute our business strategy, our ability to complete required studies, establish product safety and efficacy, obtain and maintain regulatory authorizations, the risk that competitors market the same or similar products, our ability execute commercialization or strategic-partnering arrangements, the risk that that the market or demand for any resulting product we seek to commercialize in the future could be less than expected or projected, our ability to meet our debt obligations and the negative financial and operational consequences of failing to do so, the possibility that our expectations and perceived benefits with respect to our business and product development plan and strategic transactions we may pursue prove to be incorrect, and risks with respect to our ability to negotiate and execute definitive agreements, satisfy closing conditions, obtain required approvals with respect to any such strategic transaction. There can be no assurance that the Company’s goals and milestones will be achieved, that the Company or its collaborators will receive or maintain necessary regulatory authorizations or that any initiative will ultimately generate revenue.

There can be no assurance that additional funding will be received, H.R. 10150 or other proposed legislation will be enacted in its current form or at all, regulatory policies will change, regulatory or commercialization milestones will be achieved, or any product or initiative will ultimately generate revenue. Additional risks are described in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, the Form S-1 filed on August 7, 2026, as amended, and the final prospectus filed pursuant to Rule 424(b)(3) on August 28, 2026.

Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any such statements whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Contact
Endovia Health Sciences
investors@endoviasciences.com

Media Contact
Angela Gorman
AMWPR
angela@amwpr.com
917-348-0083